Relifex Tablets 500 mg

  • Name:

    Relifex Tablets 500 mg

  • Company:
    info
  • Active Ingredients:

    Nabumetone

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 21/04/20

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 9/1/2019

Click on this link to Download PDF directly

Mylan IRE Healthcare Limited

Mylan IRE Healthcare Limited

Company Products

Medicine NameActive Ingredients
Medicine Name ALDARA 5% CREAM Active Ingredients Imiquimod
Medicine Name Ancotil 2.5g/250ml Solution for Infusion Active Ingredients Flucytosine
Medicine Name Brufen 400mg film-coated Tablets Active Ingredients Ibuprofen
Medicine Name Brufen 600mg film-coated tablets Active Ingredients Ibuprofen
Medicine Name Brufen Paediatric 100mg/5ml Oral Suspension Active Ingredients Ibuprofen
Medicine Name Brufen Retard 800mg prolonged release tablets Active Ingredients Ibuprofen
Medicine Name Calvidin 600mg/400IU Chewable Tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Cibacen 10mg Film Coated Tablet Active Ingredients Benazepril Hydrochloride
Medicine Name Cibacen 5mg Film Coated Tablets Active Ingredients Benazepril Hydrochloride
Medicine Name Clozaril 100mg Tablets Active Ingredients Clozapine
Medicine Name Clozaril 25mg Tablets Active Ingredients Clozapine
Medicine Name Colifoam 10% w/w Rectal Foam Active Ingredients Hydrocortisone Acetate
Medicine Name Colofac 135mg Tablets Active Ingredients Mebeverine Hydochloride
Medicine Name Creon 10000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon 25000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon for Children 5000 Gastro-resistant Granules Active Ingredients Pancreatin
Medicine Name Cyklokapron 500mg Tablets Active Ingredients Tranexamic Acid
Medicine Name Dalmane 15mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Dalmane 30mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Desunin 4000IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name Desunin 800IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name DIFFLAM ORAL RINSE Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM SPRAY Active Ingredients Benzydamine Hydrochloride
Medicine Name Dona 1500mg Powder for Oral Solution Active Ingredients Glucosamine Sulfate, Sodium Chloride
Medicine Name Dona 500mg Capsules Active Ingredients Glucosamine Sulfate, Sodium Chloride
1 - 0 of 95 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 21 April 2020 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 9 January 2019 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 9 January 2019 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 2 July 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Marketing Authorisation Holder Transfer from Meda Health Sales Ireland Limited to Mylan IRE Healthcare Limited

Updated on 2 July 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 14 February 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 4.2: Information added$0In section 4.3: Contraindications added$0$0In section 4.4: Specials warnings added/expanded$0$0In section 4.5: Medicines added/removed that interaction with Relifex$0$0In section 4.6: Information added$0$0In section 4.7:Information added wrt dizziness andconfusion$0$0In section 4.8: Adverse events listed by system organ class and frequency. Undesirable effects added.$0$0In section 4.9: Information added regarding symptoms, signs and treatment$0$0In section 5.1: Pharmacodynamic information added$0$0In section 5.2: Pharmacokinetic information added$0$0$0

Updated on 14 February 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 14 February 2018 PIL

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Free text change information supplied by the pharmaceutical company

In section 4.2: Information added$0In section 4.3: Contraindications added$0$0In section 4.4: Specials warnings added/expanded$0$0In section 4.5: Medicines added/removed that interaction with Relifex$0$0In section 4.6: Information added$0$0In section 4.7:Information added wrt dizziness andconfusion$0$0In section 4.8: Adverse events listed by system organ class and frequency. Undesirable effects added.$0$0In section 4.9: Information added regarding symptoms, signs and treatment$0$0In section 5.1: Pharmacodynamic information added$0$0In section 5.2: Pharmacokinetic information added$0$0$0

Updated on 15 June 2015 PIL

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

In section 6.5: the nature of the container has changed
In section 10: the date of revision has changed

Updated on 15 June 2015 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

In section 6.5: the nature of the container has changed
In section 10: the date of revision has changed

Updated on 26 January 2011 SmPC

Reasons for updating

  • Change to product name
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Change to product name: name to be extended to full name which is Relifex 500mg Film-coated Tablets
In section 1: name to be extended to full marketing name
In section 2: Additional text is added and also a referral to section 6.1
In section 3: The text 'Film-coated tablet' is added
In section 4.2: Additional text added relating to how indesirable effects may be minimised by using the lowest dose for the shortest time
In section 4.3: Additional contradindications are added - in relation to severe heart failure and use in patients with a history of gastrointestinal bleeding & perforation related to previous NSAID use
In section 4.4: Additional text added in relation to using the lowest dose for the shortest time to minimise undesirable effects. Added warnings about gastrointestinal bleeding, ulceration and perforation, use in elderly, cardiovasular and cerebrovascular effects, female fertility, serious skin reactions, concomitant use of NSAIDs
In section 4.5: Additional warnings regarding anti-coagulants, anti-platelet agents, SSRIs,
In section 4.8: Additional warnings added
In section 5.1: The ATC code is added
In section 6.1: E numbers are added to the excipients
In section 6.4: The storage conditions are changed to instruct to keep the carton in the the outer carton to protect from light
In section 6.5: Description of nature and contents of container have changed
In section 9: Would like to use the new wording for date of first authorisation and date of last renewal
In section 10: Date of revision was chaned to July 2010

Updated on 26 January 2011 PIL

Reasons for updating

  • Change to product name
  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Change to product name: name to be extended to full name which is Relifex 500mg Film-coated Tablets
In section 1: name to be extended to full marketing name
In section 2: Additional text is added and also a referral to section 6.1
In section 3: The text 'Film-coated tablet' is added
In section 4.2: Additional text added relating to how indesirable effects may be minimised by using the lowest dose for the shortest time
In section 4.3: Additional contradindications are added - in relation to severe heart failure and use in patients with a history of gastrointestinal bleeding & perforation related to previous NSAID use
In section 4.4: Additional text added in relation to using the lowest dose for the shortest time to minimise undesirable effects. Added warnings about gastrointestinal bleeding, ulceration and perforation, use in elderly, cardiovasular and cerebrovascular effects, female fertility, serious skin reactions, concomitant use of NSAIDs
In section 4.5: Additional warnings regarding anti-coagulants, anti-platelet agents, SSRIs,
In section 4.8: Additional warnings added
In section 5.1: The ATC code is added
In section 6.1: E numbers are added to the excipients
In section 6.4: The storage conditions are changed to instruct to keep the carton in the the outer carton to protect from light
In section 6.5: Description of nature and contents of container have changed
In section 9: Would like to use the new wording for date of first authorisation and date of last renewal
In section 10: Date of revision was chaned to July 2010

Updated on 12 November 2003 PIL

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Updated on 12 November 2003 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 26 August 2003 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 26 August 2003 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 22 July 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 22 July 2003 PIL

Reasons for updating

  • New SPC for medicines.ie